Hasil Pencarian - Emmanuel Okoye

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Governance paradigm in public administration and the dilemma of national question in Nigeria

    Governance paradigm in public administration and the dilemma of national question in Nigeria oleh Okey Marcellus Ikeanyibe, Ogbonnaya Eze Ori, Arinze Emmanuel Okoye

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

    Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing oleh Thomas Eigentler, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Claas Ulrich, Brian Stein, Jessica L Geiger, Emmanuel Okoye, Melissa Mathias, Jocelyn Booth, Siyu Li, Matthew G Fury

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

    Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis oleh Dirk Schadendorf, Chieh-I Chen, Zhen Chen, Israel Lowy, Elizabeth Stankevich, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Anne Lynn S Chang, Emmanuel Okoye, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski, Medha Sasane, Alesha A Thai, Suk-Young Yoo, Vera Mastey

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

    428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) oleh Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

    High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma oleh Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: